310 related articles for article (PubMed ID: 10353386)
1. Genetically altered mouse models for identifying carcinogens.
Tennant RW; Stasiewicz S; Mennear J; French JE; Spalding JW
IARC Sci Publ; 1999; (146):123-50. PubMed ID: 10353386
[No Abstract] [Full Text] [Related]
2. Medium-term bioassays in rats for rapid detection of the carcinogenic potential of chemicals.
Shirai T; Hirose M; Ito N
IARC Sci Publ; 1999; (146):251-72. PubMed ID: 10353390
[No Abstract] [Full Text] [Related]
3. The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI.
MacDonald J; French JE; Gerson RJ; Goodman J; Inoue T; Jacobs A; Kasper P; Keller D; Lavin A; Long G; McCullough B; Sistare FD; Storer R; van der Laan JW
Toxicol Sci; 2004 Feb; 77(2):188-94. PubMed ID: 14657512
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice.
Mahler JF; Flagler ND; Malarkey DE; Mann PC; Haseman JK; Eastin W
Toxicol Pathol; 1998; 26(4):501-11. PubMed ID: 9715509
[TBL] [Abstract][Full Text] [Related]
5. Investigations of clofibrate in alternative carcinogenicity models.
Santostefano MJ; Hoivik DJ; Miller RT
Int J Toxicol; 2005; 24(5):285-8. PubMed ID: 16257848
[No Abstract] [Full Text] [Related]
6. Short-and medium-term carcinogenicity tests: simple initiation-promotion assay systems.
Tsuda H; Park CB; Moore MA
IARC Sci Publ; 1999; (146):203-49. PubMed ID: 10353389
[No Abstract] [Full Text] [Related]
7. The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens.
Eastin WC; Haseman JK; Mahler JF; Bucher JR
Toxicol Pathol; 1998; 26(4):461-73. PubMed ID: 9715504
[TBL] [Abstract][Full Text] [Related]
8. P53+/- hemizygous knockout mouse: overview of available data.
Storer RD; French JE; Haseman J; Hajian G; LeGrand EK; Long GG; Mixson LA; Ochoa R; Sagartz JE; Soper KA
Toxicol Pathol; 2001; 29 Suppl():30-50. PubMed ID: 11695560
[TBL] [Abstract][Full Text] [Related]
9. Transgenic mouse models for the identification of human carcinogens: a European perspective.
van Kreijl CF; van Steeg H
Toxicol Pathol; 1998; 26(6):757-8. PubMed ID: 9864092
[No Abstract] [Full Text] [Related]
10. Rapid carcinogenicity testing system with transgenic mice harboring human prototype c-HRAS gene.
Yamamoto S; Hayashi Y; Mitsumori K; Nomura T
Lab Anim Sci; 1997 Apr; 47(2):121-6. PubMed ID: 9150488
[TBL] [Abstract][Full Text] [Related]
11. Highlights of International meeting on Alternative Methods of Carcinogenicity Testing, Leesburg, VA, November 1-3, 2000, Sponsored by the Health and Environmental Sciences Institute.
Jollow DJ
J Agromedicine; 2004; 9(2):427-9. PubMed ID: 19785235
[No Abstract] [Full Text] [Related]
12. Use of genetically modified mouse models for evaluation of carcinogenic risk: considerations for the laboratory animal scientist.
Recio L; Everitt J
Comp Med; 2001 Oct; 51(5):399-405. PubMed ID: 11924798
[TBL] [Abstract][Full Text] [Related]
13. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
Cohen SM
Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
[TBL] [Abstract][Full Text] [Related]
14. [Development of animal models for carcinogenesis by transgenesis. Transgenic mouse models for cancer research].
Katsuki M
Jikken Dobutsu; 1993 Jul; 42(3):281-2. PubMed ID: 8354348
[No Abstract] [Full Text] [Related]
15. Carcinogenic chemical-response "fingerprint" for male F344 rats exposed to a series of 195 chemicals: implications for predicting carcinogens with transgenic models.
Johnson FM
Environ Mol Mutagen; 1999; 34(4):234-45. PubMed ID: 10618171
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol.
Lina BA; Woutersen RA; Bruijntjes JP; van Benthem J; van den Berg JA; Monbaliu J; Thoolen BJ; Beems RB; van Kreijl CF
Toxicol Pathol; 2004; 32(2):192-201. PubMed ID: 15200157
[TBL] [Abstract][Full Text] [Related]
17. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens.
French J; Storer RD; Donehower LA
Toxicol Pathol; 2001; 29 Suppl():24-9. PubMed ID: 11695559
[TBL] [Abstract][Full Text] [Related]
18. The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
Tamaoki N
Toxicol Pathol; 2001; 29 Suppl():81-9. PubMed ID: 11695564
[TBL] [Abstract][Full Text] [Related]
19. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing.
Venkatachalam S; Tyner SD; Pickering CR; Boley S; Recio L; French JE; Donehower LA
Toxicol Pathol; 2001; 29 Suppl():147-54. PubMed ID: 11695551
[TBL] [Abstract][Full Text] [Related]
20. CB6F1-rasH2 mouse: overview of available data.
Usui T; Mutai M; Hisada S; Takoaka M; Soper KA; McCullough B; Alden C
Toxicol Pathol; 2001; 29 Suppl():90-108. PubMed ID: 11695565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]